Home › Research › Drug development
Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease
Elghanam Y, Purja S, Kim EY.. Journal of Alzheimer's disease : JAD, 2024-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer's disease (AD) is a neurodegenerative disease that imposes economic and societal burden. Biomarkers have played a crucial role in the recent approval of aducanumab and lecanemab as disease-modifying therapies which marked a significant milestone for the treatment of AD. The inclusion of biomarkers in AD trials facilitates precise diagnosis, monitors safety, demonstrates target engagement, and supports disease modification.
What this study adds
Evidence grade: Low
This is a trial. This paper states that biomarkers played a crucial role in the recent approval of aducanumab and lecanemab as disease-modifying therapies. Reported effect size: 29.87%; 34.73%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Elghanam, Y., Purja, S., & Kim, E. Y. (2024). Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-240008
Vancouver
Elghanam Y, Purja S, Kim EY. Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2024. doi:10.3233/jad-240008. PMID: 38669547.
BibTeX
@article{elghanam2024-38669547,
author = {Elghanam, Y. and Purja, S. and Kim, E. Y.},
title = {{Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2024},
doi = {10.3233/jad-240008},
pmid = {38669547},
url = {https://doi.org/10.3233/jad-240008}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Biomarkers have played a crucial role in the recent approval of aducanumab and lecanemab as disease-modifying therapies which marked a significant milestone for the treatment of AD.
- The inclusion of biomarkers in AD trials facilitates precise diagnosis, monitors safety, demonstrates target engagement, and supports disease modification.
- Objective This study analyzed the utilization state and trends of biomarkers as endpoints in AD trials.
- Methods In this retrospective study, trials were collected by searching clinicaltrials.gov using the term "Alzheimer".
Why it matters
This paper states that biomarkers played a crucial role in the recent approval of aducanumab and lecanemab as disease-modifying therapies. It analyzed how biomarkers are used as endpoints in Alzheimer's disease trials to support diagnosis, safety monitoring and disease modification.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Effect size29.87%; 34.73%
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Eun Young Kim: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Chung-Ang University: institution h-index 325 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38669547) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development from nearby years
Also in Drug development
124 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.